摘要
目的探究雷贝拉唑对慢性萎缩性胃炎患者血清胃泌素-17(G-17)、胃蛋白酶原(PGⅠ,PGⅡ)及胃动素(MOT)水平影响。方法收集慢性萎缩性胃炎患者66例,根据随机对照表分为对照组和试验组,其中试验组33例,对照组33例,2组均给予常规治疗和对症治疗,对照组给予奥美拉唑肠溶胶囊1粒/次口服,1次/天,盐酸左氧氟沙星片0.2 g/次口服,2次/天,呋喃唑酮片0.1 g/次口服,2次/天;试验组给予雷贝拉唑钠肠溶片20 mg/次口服,2次/天,左氧氟沙星以及呋喃唑酮等药物的用法和用量与对照组保持一致。2组患者1个周期均为14 d,共治疗1个周期。治疗结束后对比分析2组临床疗效、血清胃泌素-17、胃蛋白酶原、胃动素水平以及不良反应。结果治疗后,与对照组相比,试验组临床总有效率较高(P<0.05),治疗后2组G-17、PGI、PGⅠ/PGⅡ、MOT水平升高(P<0.05),与对照组相比,试验组G-17、PGI、PGR、MOT水平较高(P<0.05),2组PGⅡ水平治疗前后,差异无统计学意义。2组不良反应相比,差异无统计学意义。结论雷贝拉唑对慢性萎缩性胃炎患者的临床疗效显著,有效提高患者血清胃泌素-17、胃蛋白酶原及胃动素水平,改善临床症状,药物安全性高。
Objective To investigate the effect of rabeprazole on chronic atrophic gastritis in patients with serum gastrin-17,pepsinogen and motilin levels. Methods 66 patients with chronic atrophic gastritis were selected and randomly divided into control group and experimental group by random number table with 33 cases in each group. The patients in the both groups were give regular treatment. Patients in control group were given omeprazole enteric-coated capsules,one capsules per time,1 times per day,levofloxacin hydrochloride tablets 0. 2 g / times orally,2 times a day and furazolidone tablets 0. 1 g / times orally,2 times per day. Patients in experimental group revieved Rabeprazole sodium enteric coated tablets（ letter guardforce） 20 mg / orally,2 times per day. The usage and dosage of levofloxacin and other drugs were consistent with that of control group. A cycle of 2groups of patients were 14 d,a total of 1 cycles of treatment. The clinical efficacy,serum gastrin,motilin,pepsinogen-17 and adverse reaction were compared between the two groups. Results Compared with control group,the clinical total effective rate in experimental group were higher（ P〈0. 05）.The G-17,PGI,PGR and MOT levels were higher after treatment（ P〈0. 05）. Compared with control group,the G-17、PGI、PGR and MOT levels were higher（ P〈0. 05）. There was no significant difference between two groups before and after the treatment of PGⅡ. There was no significant difference in adverse reactions between two groups. Conclusion The clinical efficacy of rabeprazole on chronic atrophic gastritis is significant,effectively improve the serum gastrin-17,pepsinogen and plasma motilin levels,improve the clinical symptoms and drug safety.
出处
《中国生化药物杂志》
CAS
2016年第3期76-78,共3页
Chinese Journal of Biochemical Pharmaceutics
